Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was downgraded by research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Briefing.com reports.
Several other equities research analysts have also recently weighed in on BAYRY. HSBC raised Bayer Aktiengesellschaft from a “reduce” rating to a “hold” rating in a research note on Tuesday, October 10th. They noted that the move was a valuation call. Deutsche Bank Aktiengesellschaft lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Berenberg Bank lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, Redburn Atlantic downgraded shares of Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a research note on Monday, September 25th. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Bayer Aktiengesellschaft Stock Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 14.76%. The firm had revenue of $11.26 billion for the quarter, compared to analyst estimates of $12.62 billion. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.69 earnings per share for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Five stocks we like better than Bayer Aktiengesellschaft
- Airline Stocks – Top Airline Stocks to Buy Now
- Safeguard your portfolio with these three bargain stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Membership clubs gain leverage for the consumer rebound
- Learn Technical Analysis Skills to Master the Stock Market
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.